Lutetium-177-labeled DOTA-PSMA-617is a popular radiodrug (known commercially as Pluvicto) for the treatment of advanced prostate cancer,40−44 and Klika, as part of the research group that reportedDOTA-PSMA-617, characterized the molecular structure of DOTA-PSMA-617by NMR.44 Here, FOLH1 is linked to prostate cancer.